Singapore Kidney Cancer Therapeutics Market Analysis

Singapore Kidney Cancer Therapeutics Market Executive Summary

Singapore Kidney Cancer Therapeutics Market is at around $7.5 Mn in 2023 and is projected to reach $11 Mn in 2030, exhibiting a CAGR of 5.46% during the forecast period.

One feature of kidney cancer is the appearance of malignant tumors in the kidneys. Renal cell carcinoma mostly strikes the elderly, usually those between the ages of 50 and 70. Common symptoms include blood in the urine, pain in the flanks or back, an abdominal tumor or lump, fatigue, loss of appetite, unintentional weight loss, and lack of appetite. Though risk factors like obesity, smoking, high blood pressure, and family history might raise the chance of acquiring the disease, the precise cause of kidney cancer is frequently unknown. Radical nephrectomy or renal-sparing techniques are the main treatments in Singapore when the disease is detected in its early stages. However, a sizable fraction of RCC patients receive a late diagnosis; in Singapore, it is estimated that approximately 38% of individuals with RCC initially had advanced or metastatic renal cell carcinoma (RCC). Since RCC is a malignancy resistant to chemotherapy, the primary therapeutic options for those patients are immunotherapy and targeted treatments, occasionally in conjunction with radical nephrectomy.

Kidney cancer is the 13th most common cancer in Singapore with nearly 12,000 new cases reported in 2020. Renal cell carcinomas (RCCs) comprise 2-3% of all adult cancer cases and 80–85% of cases of kidney cancer. RCC is most commonly diagnosed in the elderly, with a median age of 64 years. Male patients outweigh female patients by a ratio of 3:2. The market is growing due Increasing Prevalence of Renal Cell Carcinoma, Demand for Immunotherapies, and Technological advancements. However, Limited Awareness, Side effects, and High cost of treatment restrict the growth and potential of the market.

Merck's immunotherapy drug Keytruda (pembrolizumab) has shown remarkable efficacy in treating kidney cancer.

Market Dynamics

Market Growth Drivers

Increasing Prevalence of Renal Cell Carcinoma: An estimated 403,000 people worldwide receive a kidney cancer diagnosis each year, making up 2.2% of all new cancer diagnoses. Nearly 90% of kidney cancer diagnoses are of renal cell carcinoma (RCC), the most common kind of the disease. Renal cell carcinoma (RCC) is a cancer that affects approximately 4% of adult cancer cases; 270,000 new cases are reported worldwide each year. 2010 saw 58,000 new cases of RCC discovered in the US alone, with about 13,000 deaths associated with the disease. These numbers are predicted to increase to 13,780 fatalities and 76,080 new cases in 2021. RCC affects men twice as frequently as it does women. Between 50 and 70 years old is the typical diagnostic age range.

Demand for Immunotherapies: The widespread use of tailored therapies to specific patient subpopulations will be pushed by a growing desire for innovative immunotherapies and immune-oncologic medicines. In first- and second-line RCC situations, programmed death-1 (PD-1) inhibitors are intended to replace TKIs and mTOR inhibitors as the mainstay of therapy. In the first-line scenario, combination regimens—particularly those containing PD-1 inhibitors—will be introduced to address significant unmet requirements, enhance progression-free survival, overcome tumor resistance, and preserve quality of life. As a result, this kind of treatment is promoting market expansion.

Technological advancements: Kidney cancer treatments market growth is being driven by oncology's intense research and development efforts. Novel therapies are created when academic institutions, biotech businesses, and healthcare facilities work together. Singapore's status as a clinical trial hub in the area draws pharmaceutical companies from around the world to test and launch innovative treatments.

Market Restraints

Limited Awareness: There is still a portion of the public that is not sufficiently informed about the risk factors and early warning indicators of kidney cancer, despite intensified efforts. Insufficient knowledge may lead to postponed diagnosis and therapy, hence diminishing the efficacy of therapeutic approaches. Furthermore, it's possible that not enough people have access to or participate in routine screening programs, especially in lower-income populations.

Side effects: The main adverse effects of these medications for kidney cancer may restrict the market's expansion during the projected period. Effects including fever, rashes, and appetite loss can hinder the market's expansion.

High cost of treatment: Advanced treatments for kidney cancer are costly, especially immunotherapies and targeted medicines. Even with insurance coverage, many patients may find the high expense of these treatments to be a substantial obstacle. For some population segments, this financial burden prevents them from accessing the newest and most effective treatments.

Regulatory Landscape and Reimbursement Scenario

The Ministry of Health (MOH) is in charge of overseeing healthcare regulations in Singapore and establishing standards and policies to guarantee high-quality treatment. Medical goods, including prescription drugs and medical equipment, are governed by the Health Sciences Authority (HSA). Physicians' professional behavior is regulated by the Singapore Medical Council (SMC). Statutory boards such as Singapore Health Services (SingHealth) and the National Healthcare Group (NHG) oversee public healthcare facilities. Rules provide a strong emphasis on patient safety, high-quality care, and cost-effectiveness. A combination of public and private healthcare providers guarantees that all inhabitants have widespread access to complete services.

The Ministry of Health in Singapore is implementing the "3 Beyonds" strategy: Beyond hospital to the community; Beyond quality to value; and Beyond healthcare to health. This approach aims to adapt the country's world-class health system to reflect medical progress and serve its aging population, which is expected to double by 2030 and account for a quarter of the population. The system is performing exceptionally well by many measures, including per-capita costs and health outcomes. Delaying the onset of chronic diseases, boosting home-based care for managing chronic diseases, and coordinating care for individuals with expensive disorders are some of the major policy challenges Singapore is addressing.

Competitive Landscape

Here are some of the major key players in the Singapore Lipid Disorder Therapeutics Market:

Key Players

• Merck (Germany)
• Pfizer Inc (U.S.)
• AstraZeneca (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• Dr. Reddy's Laboratories Ltd (India)
• Sun Pharmaceutical Industries Ltd (India)
• Novartis AG (Switzerland)
• Sanofi (France)
• Takeda Pharmaceutical Company Limited (Japan)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Abbott (U.S.)